<DOC>
	<DOC>NCT00902681</DOC>
	<brief_summary>This bioequivalence (BE) study is to satisfy FDA regulatory requirements for extended releases drug product transfer from Zwickau, Germany to Vega Baja, Puerto-Rico.</brief_summary>
	<brief_title>A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviazâ„¢) In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Healthy male and/or female subjects Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 Subjects with evidence or history of clinically significant urologic diseases A positive urine drug screen Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Bioequivalence, Pharmacokinetics</keyword>
</DOC>